Skip to main content
. Author manuscript; available in PMC: 2011 Aug 15.
Published in final edited form as: J Infect Dis. 2010 Aug 15;202(4):595–605. doi: 10.1086/654816

Fig. 6.

Fig. 6

Comparison of pre-infection NAb responses among men and women vaccine recipients (n=90 evaluated in Fig. 1) as measured with the tier 1 and tier 2 reference strains evaluated in Fig. 1. Positive response rates (frequency of positive results at ≥1:10 plasma dilution), titers of NAbs and M-B curves were derived from results obtained in the TZM-bl (A) and U87.CD4.CCR5.CXCR4 (B) assays. Subject-specific and group averages in M-B plots are shown as light and heavy lines, respectively, and are for the tier 2 viruses only.